Abstract
Uterine body cancer (UBC) makes up 7.1% of malignant tumors in women and ranks 6th in the structure of the incidence of malignant tumors in women in the world after breast cancer, cervical cancer, colorectal cancer, lung and thyroid cancer. In developed countries, it is the most common malignant tumor of the female genital organs. The study included 105 patients with a diagnosis of stage I uterine body cancer, the patients were divided into 2 groups: I - the main group consists of 60 patients who received preoperative brachytherapy (Total focal dose (TFD) = 16-20Gy). Control group II consisted of 45 patients who, after curettage of the uterine cavity, were immediately operated on in the volume of extirpation of the uterus with appendages and routinely received combined radiation therapy: from distance gamma therapy (DGT) TFD = 44 Gy, from brachytherapy TFD = 20 Gy. All biological materials obtained during curettage of the uterine cavity and as a result of surgery in both groups were subjected to immunohistochemistry. The mutant p53 gene and the apoptosis regulator bcl-2 were studied by immunohistochemical method.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
